Design and Efficacy of Nanogels Formulations for Intranasal Administration

Aderibigbe, Blessing Atim; Naki, Tobeka

doi:10.3390/molecules23061241

Cited by 52 publications

(23 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, the missing or minimal ability of these proteins to cross cellular barriers without a carrier restricts their therapeutic use on well-exposed and accessible targets, as they cannot cross, for example, the blood–brain barrier (BBB) in sufficient amounts [ 32 ]. As a consequence, only roughly 0.1–0.4% of an individual IgG plasma concentration can be found in the CNS [ 33 , 34 , 35 ], and this can only be enhanced by using either trans-cellular transport mechanisms like transferrin- [ 36 ] or insulin receptor-mediated transcytosis [ 37 ], or by exploiting pharmaceutical particulate formulations [ 38 , 39 ]. On the contrary, antibody formats with a reduced size, such as Fab, single chain variable fragments (scFvs) or sdAbs can more efficiently diffuse into tumors and cross specific tissue barriers, e.g., the BBB, without losing their main properties, such as affinity and specificity for their antigen [ 30 , 40 , 41 ].…”

Section: General Considerations Relating To the Distribution And Tissue Penetration Of Full-length Igg Antibodiesmentioning

confidence: 99%

Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration

2021

View full text Add to dashboard Cite

IgG antibodies are some of the most important biopharmaceutical molecules with a high market volume. In spite of the fact that clinical therapies with antibodies are broadly utilized in oncology, immunology and hematology, their delivery strategies and biodistribution need improvement, their limitations being due to their size and poor ability to penetrate into tissues. In view of their small size, there is a rising interest in derivatives, such as single-domain antibodies and single-chain variable fragments, for clinical diagnostic but also therapeutic applications. Smaller antibody formats combine several benefits for clinical applications and can be manufactured at reduced production costs compared with full-length IgGs. Moreover, such formats have a relevant potential for targeted drug delivery that directs drug cargo to a specific tissue or across the blood–brain barrier. In this review, we give an overview of the challenges for antibody drug delivery in general and focus on intranasal delivery to the central nervous system with antibody formats of different sizes.

show abstract

Section: General Considerations Relating To the Distribution And Tissue Penetration Of Full-length Igg Antibodiesmentioning

confidence: 99%

Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration

2021

View full text Add to dashboard Cite

show abstract

“…Currently, nanogels possess the ability to hold active molecules, macromolecules, and drugs together, which are considered promising drug delivery vehicles and have been exploited in many challenges associated with different kinds of pathologies including AD (Aderibigbe and Naki, 2018). A recent study reveals that the delivery of deferoxamine in the form of nanogels using the chitosan and tripolyphosphate via ionotropic method could be one of the effective therapies against AD (Ashrafi et al, 2020).…”

Section: Nanogelsmentioning

confidence: 99%

Nanomedicine: A Promising Way to Manage Alzheimer’s Disease

Khan

Mir

Ngowi

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a devastating disease of the aging population characterized by the progressive and slow brain decay due to the formation of extracellular plaques in the hippocampus. AD cells encompass tangles of twisted strands of aggregated microtubule binding proteins surrounded by plaques. Delivering corresponding drugs in the brain to deal with these clinical pathologies, we face a naturally built strong, protective barrier between circulating blood and brain cells called the blood–brain barrier (BBB). Nanomedicines provide state-of-the-art alternative approaches to overcome the challenges in drug transport across the BBB. The current review presents the advances in the roles of nanomedicines in both the diagnosis and treatment of AD. We intend to provide an overview of how nanotechnology has revolutionized the approaches used to manage AD and highlight the current key bottlenecks and future perspective in this field. Furthermore, the emerging nanomedicines for managing brain diseases like AD could promote the booming growth of research and their clinical availability.

show abstract

“…In AD related to microglial activation, nanogels have shown promising effects in holding various drug candidates and macromolecules [161]. In one recently published report, deferoxamine nanogels and chitosan showed a significant anti-Alzheimer's effect [162].…”

Section: Dendrimers and Nanogelsmentioning

confidence: 99%

Mechanisms Involved in Microglial-Interceded Alzheimer’s Disease and Nanocarrier-Based Treatment Approaches

Shadab

Alhakamy

Alfaleh

et al. 2021

JPM

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a common neurodegenerative disorder accountable for dementia and cognitive dysfunction. The etiology of AD is complex and multifactorial in origin. The formation and deposition of amyloid-beta (Aβ), hyperphosphorylated tau protein, neuroinflammation, persistent oxidative stress, and alteration in signaling pathways have been extensively explored among the various etiological hallmarks. However, more recently, the immunogenic regulation of AD has been identified, and macroglial activation is considered a limiting factor in its etiological cascade. Macroglial activation causes neuroinflammation via modulation of the NLRP3/NF-kB/p38 MAPKs pathway and is also involved in tau pathology via modulation of the GSK-3β/p38 MAPK pathways. Additionally, microglial activation contributes to the discrete release of neurotransmitters and an altered neuronal synaptic plasticity. Therefore, activated microglial cells appear to be an emerging target for managing and treating AD. This review article discussed the pathology of microglial activation in AD and the role of various nanocarrier-based anti-Alzeihmenr’s therapeutic approaches that can either reverse or inhibit this activation. Thus, as a targeted drug delivery system, nanocarrier approaches could emerge as a novel means to overcome existing AD therapy limitations.

show abstract

Design and Efficacy of Nanogels Formulations for Intranasal Administration

Cited by 52 publications

References 91 publications

Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration

Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration

Nanomedicine: A Promising Way to Manage Alzheimer’s Disease

Mechanisms Involved in Microglial-Interceded Alzheimer’s Disease and Nanocarrier-Based Treatment Approaches

Contact Info

Product

Resources

About